arrow_back
Medical Information
  • GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. KITE and the KITE logo are trademarks of Kite Pharma, Inc. © 2023 Gilead Sciences, Inc. All rights reserved. US-UNBP-2480 12/23

Scientific Presentations.

Oral and Poster Presentations: Gilead and Kite sponsored studies
December 9 - 12, 2023
San Diego, CA

Oral Presentations
  • Saturday: Abstracts 103, 106, 107, 223, 224, 226, 244
  • Monday: Abstracts 894, 1023, 1029
Poster Presentations
  • Saturday: Abstracts 1638, 1761, 2120, 2121, 2336
  • Sunday: Abstract 3494
  • Monday: Abstracts 4864, 4865, 4868, 4869, 4424, 5082, 5136
ePubs
  • Pub 6899

Oral Presentations

The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available.
Saturday, December 9, 2023
Abstract 103
Abstract 106
Abstract 107
Abstract 223
Abstract 224
Abstract 226
Abstract 244
Session 705 | Abstract 103

Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Presenting author: Michael Cook

Session: 9:30 am – 11:00 am PST*
Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data
Room 6A • 9:30 am PST* (Poster discussion)

View abstract

Session 705 | Abstract 106

Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study

Presenting author: Andre Goy

Session: 9:30 am – 11:00 am PST*
Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data
Room 6A • 10:15 am PST* (Poster discussion)

View abstract

Session 705 | Abstract 107

Real-world Outcomes of Brexucabtagene Autoleucel (Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics

Presenting author: Swetha Kambhampati

Session: 9:30 am – 11:00 am PST*
Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data
Room 6A • 10:30 am PST* (Poster discussion)

View abstract

Session 705 | Abstract 223

Baseline Immune State and T cell Clonal Kinetics are Associated with Response to CAR-T Therapy sin Large B-cell Lymphoma

Presenting author: Katie Maurer

Session: 2:00 pm – 3:30 pm PST*
Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Translational Data and Prognostic Factors
Room 6CF • 2:00 pm PST* (Poster discussion)

View abstract

Session 705 | Abstract 224

An Inflammatory Biomarker Signature Reproducibly Predicts CAR-T Treatment Failure in Patients with Aggressive Lymphoma Across the ZUMA Trials Cohorts

Presenting author: Sandeep Raj

Session: 2:00 pm – 3:30 pm PST*
Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Translational Data and Prognostic Factors
Room 6CF • 2:15 pm PST* (Poster discussion)

View abstract

Session 705 | Abstract 226

Pre- and post-treatment Immune Contexture Correlates with Long Term Response in Large B cell Lymphoma Patients Treated with Axicabtagene ciloleucel (axi-cel)

Presenting author: Mike Mattie

Session: 2:00 pm – 3:30 pm PST*
Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Translational Data and Prognostic Factors
Room 6CF • 2:45 pm PST*

View abstract

Session 803 | Abstract 244

Advancing CAR-T Therapy in Acute Lymphoblastic Leukemia: Multi-Omic Analyses of CD19-Directed CAR-T Cells Enabled by an Ex Vivo Co-Culture Platform

Presenting author: Mike Mattie

Session: 2:00 pm – 3:30 pm PST*
Emerging Tools, Techniques and Artificial Intelligence in Hematology: Emerging Technologies for Understanding Benign and Malignant Hematology
Room 6CF • 2:45 pm PST*

View abstract

Monday, December 11, 2023
Abstract 894
Abstract 1023
Abstract 1029
Session 704 | Abstract 894

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Presenting author: Julio Chavez

Session: 2:45 pm – 4:15 pm PST*
Cellular Immunotherapies: Early Phase and Investigational Therapies: Improving CAR-T Therapies for B-Cell Malignancies
Room 6A • 4:00 pm PST* (Poster discussion)

View abstract

Session 704 | Abstract 1023

Phase 1 Study of CART-ddBCMA for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-year Follow-up in All Patients

Presenting author: Matthew Frigault

Session: 4:30 pm – 6:00 pm PST*
Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR-T Cell Therapies for Multiple Myeloma and B-Cell Lymphomas
Room 6A • 5:00 pm PST* (Poster discussion)

View abstract

Session 705 | Abstract 1029

Real-world Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

Presenting author: Evandro Bezerra

Session: 4:30 pm – 6:00 pm PST*
Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B-Cell Lymphomas: Clinical Trial and Real World Evidence
Room 6CF • 5:00 pm PST* (Poster discussion)

View abstract


*Presentation time and date subject to change.

Poster Presentations

Saturday–Monday
December 9 - 11, 2023 • 5:30 – 7:30 PST*
San Diego Convention Center, Halls G-H

The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available.

Personal and Shared Tumor-Antigen Prioritization in Diffuse Large B Cell Lymphoma Patients undergoing CD19 CAR T cell treatment

Dimitra Karagkouni
DLBCL

Abstract 1638

Improved Overall Survival With Axicabtagene Ciloleucel vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Marie José Kersten
LBCL

Abstract 1761

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Olalekan Oluwole
MCL

Abstract 2120

Comparative Effectiveness of Axicabtagene Ciloleucel vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Swetha Kambhampati
FL

Abstract 2121

Economic burden associated with ASCT in patients with relapsed/refractory diffuse large B-cell lymphoma: a nationwide health insurance claims database study in Japan during 2012-2022

Saaya Tsutsué
DLBCL

Abstract 2336

A Propensity Score-Matched Analysis on the Outcomes of Brexucabtagene Autoleucel from ZUMA-2 Study and Allogeneic Stem Cell Transplantation from the EBMT Database in Relapsed and Refractory Post-BTKi Mantle Cell Lymphoma

Nora Liebers
MCL

Abstract 3494

Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): an Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1

Sattva Neelapu
LBCL

Abstract 4864

A Retrospective Intra-Patient Analysis from ZUMA-5: Axicabtagene Ciloleucel (Axi-Cel) Compared with Prior Standard-of-Care (SOC) Therapy in Patients with Relapsed/Refractory Follicular Lymphoma

Emmanuel Bachy
FL

Abstract 4865

Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL): 4-Year Follow-Up from the Phase 2 ZUMA-5 Trial

Sattva Neelapu
iNHL

Abstract 4868

An Updated Comparison of Clinical Outcomes from 4-year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) and the International SCHOLAR-5 External Control Cohort in Relapsed/refractory Follicular Lymphoma

John Gribben
FL

Abstract 4869

Physician Treatment Preferences in Relapsed/Refractory Follicular Lymphoma: A Discrete Choice Experiment

Markqayne Ray
MCL

Abstract 4424

Cost-effectiveness of Axicabtagene Ciloleucel versus Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma in the US

Olalekan Oluwole
FL

Abstract 5082

Matching-Adjusted Indirect Comparison (MAIC) of Brexucabtagene Autoleucel (Brexu-cel) and Pirtobrutinib in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)

Bijal Shah
MCL

Abstract 5136

ePublications

The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available.
6899 | HEOR: ZUMA-7

Statistical challenges from trials of potentially curative treatments: Validation of cure assumptions when analyzing ZUMA-7 follow-Up data of axi-cel and standard of care therapy

Anik Patel, et al.